These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 16365973)

  • 1. Tenofovir trials raise ethical issues.
    Mills E
    HIV AIDS Policy Law Rev; 2005 Aug; 10(2):31-2. PubMed ID: 16365973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings.
    Myers GM; Mayer KH
    AIDS Patient Care STDS; 2011 Feb; 25(2):63-71. PubMed ID: 21284497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A preemptive strike against HIV.
    Willyard C
    Nat Med; 2009 Feb; 15(2):126-9. PubMed ID: 19197277
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of Tenofovir gel as a PrEP on HIV infection: a mathematical model.
    Rahman SM; Vaidya NK; Zou X
    J Theor Biol; 2014 Apr; 347():151-9. PubMed ID: 24380779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tenofovir disoproxil fumarate (Viread) for the treatment of HIV infection.
    Gallant JE; Pham PA
    Expert Rev Anti Infect Ther; 2003 Oct; 1(3):415-22. PubMed ID: 15482138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral tenofovir arm of VOICE trial discontinued early.
    McEnery R
    IAVI Rep; 2011; 15(5):21. PubMed ID: 22121550
    [No Abstract]   [Full Text] [Related]  

  • 7. One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates.
    Denton PW; Othieno F; Martinez-Torres F; Zou W; Krisko JF; Fleming E; Zein S; Powell DA; Wahl A; Kwak YT; Welch BD; Kay MS; Payne DA; Gallay P; Appella E; Estes JD; Lu M; Garcia JV
    J Virol; 2011 Aug; 85(15):7582-93. PubMed ID: 21593172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Report from the XVI International AIDS Conference. Preexposure prophylaxis studies move forward.
    Sax PE
    AIDS Clin Care; 2006 Nov; 18(11):101-2. PubMed ID: 17186582
    [No Abstract]   [Full Text] [Related]  

  • 9. A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection.
    Gengiah TN; Baxter C; Mansoor LE; Kharsany AB; Abdool Karim SS
    Expert Opin Investig Drugs; 2012 May; 21(5):695-715. PubMed ID: 22394224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiretroviral vaginal gel shows promise against HIV.
    Baleta A
    Lancet; 2010 Jul; 376(9738):320. PubMed ID: 20681062
    [No Abstract]   [Full Text] [Related]  

  • 11. Disinhibition and risk compensation: scope, definitions, and perspective.
    Hogben M; Liddon N
    Sex Transm Dis; 2008 Dec; 35(12):1009-10. PubMed ID: 18936724
    [No Abstract]   [Full Text] [Related]  

  • 12. Tenofovir disoproxil fumarate (Viread).
    Porche DJ
    J Assoc Nurses AIDS Care; 2002; 13(3):100-2. PubMed ID: 12064015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. After CAPRISA 004: time to re-evaluate the HIV lexicon.
    Cates W
    Lancet; 2010 Aug; 376(9740):495-6. PubMed ID: 20709216
    [No Abstract]   [Full Text] [Related]  

  • 14. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R; Calza L
    AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early nonresponse for tenofovir regimen.
    AIDS Patient Care STDS; 2003 Nov; 17(11):603. PubMed ID: 14748354
    [No Abstract]   [Full Text] [Related]  

  • 16. Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial.
    Chi BH; Sinkala M; Mbewe F; Cantrell RA; Kruse G; Chintu N; Aldrovandi GM; Stringer EM; Kankasa C; Safrit JT; Stringer JS
    Lancet; 2007 Nov; 370(9600):1698-705. PubMed ID: 17997151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV disease progression in seroconvertors from the CAPRISA 004 tenofovir gel pre-exposure prophylaxis trial.
    Garrett NJ; Werner L; Naicker N; Naranbhai V; Sibeko S; Samsunder N; Gray C; Williamson C; Morris L; Abdool-Karim Q; Abdool-Karim SS
    J Acquir Immune Defic Syndr; 2015 Jan; 68(1):55-61. PubMed ID: 25247433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-exposure prophylaxis (PrEP) in HIV-uninfected individuals with high-risk behaviour.
    Nadery S; Geerlings SE
    Neth J Med; 2013; 71(6):295-9. PubMed ID: 23956310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tenofovir hypersensitivity to tenofovir (DRESS) syndrome in a female patient infected by HIV].
    Bayonne Kombo ES; Gathse A
    Med Mal Infect; 2013 Mar; 43(3):134-5. PubMed ID: 23434355
    [No Abstract]   [Full Text] [Related]  

  • 20. Perceptions of emtricitabine-tenofovir in HIV PrEP.
    Kruse L; Stover K; Henderson H
    HIV Clin; 2014; 26(1):1, 4-7. PubMed ID: 24855688
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.